CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance

Sandip Kapur, Ashwani Khanna, Vijay K. Sharma, Baogui Li, Manikkam Suthanthiran

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We explored the hypothesis that CD2 antigen-specific therapy would reduce intragraft gene expression and facilitate the emergence of transplantation tolerance. This postulate was tested in a murine pancreatic islet cell allograft model in which a novel mAb directed at the CD2 antigen, RM2-2 anti-CD2 mAb (RM2-2 mAb), was used to regulate CD2 antigen-dependent antiallograft response. Peritransplant administration (day -1, 0, and day +1 with respect to transplantation) of RM2-2 mAb resulted in significantly longer survival of DBA/2 pancreatic islet cell allografts in the B6AF1 recipient compared with untreated recipients. RM2-2 mAb therapy facilitated the induction of antigen-specific tolerance: whereas retransplantation with the original donor strain (DBA/2) islet ceil allograft was successful, retransplantation with a third.party donor (SJL) islet cell allograft was not. In vivo administration of RM2-2 mAb therapy resulted in a decrease in the percentage of T cells that coexpressed the CD2 antigen (demonstrated by two-color flow cytometry) and in a decrease in intragraft expression of cytotoxic cell specific granzyme B mRNA and IL-10 mRNA (detected by RT-PCR). Our data, in addition to demonstrating for the first time the efficacy of RM2-2 anti-CD2 mAb, suggest that CD2 antigen is a suitable target for the induction of transplantation tolerance.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalTransplantation
Volume62
Issue number2
DOIs
Publication statusPublished - 27 Jul 1996
Externally publishedYes

Fingerprint

CD2 Antigens
Granzymes
Islets of Langerhans
Interleukin-10
Allografts
Messenger RNA
Transplantation Tolerance
Flow Cytometry
Therapeutics
Color
Transplantation
T-Lymphocytes
Gene Expression
Antigens
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Transplantation

Cite this

CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance. / Kapur, Sandip; Khanna, Ashwani; Sharma, Vijay K.; Li, Baogui; Suthanthiran, Manikkam.

In: Transplantation, Vol. 62, No. 2, 27.07.1996, p. 249-255.

Research output: Contribution to journalArticle

Kapur, Sandip ; Khanna, Ashwani ; Sharma, Vijay K. ; Li, Baogui ; Suthanthiran, Manikkam. / CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance. In: Transplantation. 1996 ; Vol. 62, No. 2. pp. 249-255.
@article{cfcb18fe19be4bfd9870ebb8800665be,
title = "CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance",
abstract = "We explored the hypothesis that CD2 antigen-specific therapy would reduce intragraft gene expression and facilitate the emergence of transplantation tolerance. This postulate was tested in a murine pancreatic islet cell allograft model in which a novel mAb directed at the CD2 antigen, RM2-2 anti-CD2 mAb (RM2-2 mAb), was used to regulate CD2 antigen-dependent antiallograft response. Peritransplant administration (day -1, 0, and day +1 with respect to transplantation) of RM2-2 mAb resulted in significantly longer survival of DBA/2 pancreatic islet cell allografts in the B6AF1 recipient compared with untreated recipients. RM2-2 mAb therapy facilitated the induction of antigen-specific tolerance: whereas retransplantation with the original donor strain (DBA/2) islet ceil allograft was successful, retransplantation with a third.party donor (SJL) islet cell allograft was not. In vivo administration of RM2-2 mAb therapy resulted in a decrease in the percentage of T cells that coexpressed the CD2 antigen (demonstrated by two-color flow cytometry) and in a decrease in intragraft expression of cytotoxic cell specific granzyme B mRNA and IL-10 mRNA (detected by RT-PCR). Our data, in addition to demonstrating for the first time the efficacy of RM2-2 anti-CD2 mAb, suggest that CD2 antigen is a suitable target for the induction of transplantation tolerance.",
author = "Sandip Kapur and Ashwani Khanna and Sharma, {Vijay K.} and Baogui Li and Manikkam Suthanthiran",
year = "1996",
month = "7",
day = "27",
doi = "10.1097/00007890-199607270-00017",
language = "English",
volume = "62",
pages = "249--255",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance

AU - Kapur, Sandip

AU - Khanna, Ashwani

AU - Sharma, Vijay K.

AU - Li, Baogui

AU - Suthanthiran, Manikkam

PY - 1996/7/27

Y1 - 1996/7/27

N2 - We explored the hypothesis that CD2 antigen-specific therapy would reduce intragraft gene expression and facilitate the emergence of transplantation tolerance. This postulate was tested in a murine pancreatic islet cell allograft model in which a novel mAb directed at the CD2 antigen, RM2-2 anti-CD2 mAb (RM2-2 mAb), was used to regulate CD2 antigen-dependent antiallograft response. Peritransplant administration (day -1, 0, and day +1 with respect to transplantation) of RM2-2 mAb resulted in significantly longer survival of DBA/2 pancreatic islet cell allografts in the B6AF1 recipient compared with untreated recipients. RM2-2 mAb therapy facilitated the induction of antigen-specific tolerance: whereas retransplantation with the original donor strain (DBA/2) islet ceil allograft was successful, retransplantation with a third.party donor (SJL) islet cell allograft was not. In vivo administration of RM2-2 mAb therapy resulted in a decrease in the percentage of T cells that coexpressed the CD2 antigen (demonstrated by two-color flow cytometry) and in a decrease in intragraft expression of cytotoxic cell specific granzyme B mRNA and IL-10 mRNA (detected by RT-PCR). Our data, in addition to demonstrating for the first time the efficacy of RM2-2 anti-CD2 mAb, suggest that CD2 antigen is a suitable target for the induction of transplantation tolerance.

AB - We explored the hypothesis that CD2 antigen-specific therapy would reduce intragraft gene expression and facilitate the emergence of transplantation tolerance. This postulate was tested in a murine pancreatic islet cell allograft model in which a novel mAb directed at the CD2 antigen, RM2-2 anti-CD2 mAb (RM2-2 mAb), was used to regulate CD2 antigen-dependent antiallograft response. Peritransplant administration (day -1, 0, and day +1 with respect to transplantation) of RM2-2 mAb resulted in significantly longer survival of DBA/2 pancreatic islet cell allografts in the B6AF1 recipient compared with untreated recipients. RM2-2 mAb therapy facilitated the induction of antigen-specific tolerance: whereas retransplantation with the original donor strain (DBA/2) islet ceil allograft was successful, retransplantation with a third.party donor (SJL) islet cell allograft was not. In vivo administration of RM2-2 mAb therapy resulted in a decrease in the percentage of T cells that coexpressed the CD2 antigen (demonstrated by two-color flow cytometry) and in a decrease in intragraft expression of cytotoxic cell specific granzyme B mRNA and IL-10 mRNA (detected by RT-PCR). Our data, in addition to demonstrating for the first time the efficacy of RM2-2 anti-CD2 mAb, suggest that CD2 antigen is a suitable target for the induction of transplantation tolerance.

UR - http://www.scopus.com/inward/record.url?scp=0029898715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029898715&partnerID=8YFLogxK

U2 - 10.1097/00007890-199607270-00017

DO - 10.1097/00007890-199607270-00017

M3 - Article

VL - 62

SP - 249

EP - 255

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -